FDAnews Drug Daily Bulletin

Pharma Blog Watch

June 1, 2012
Where the Deals Are (Pharmalot blog)
Tracking dealmaking in biopharma is more than a passtime, of course, blogger Ed Silverman writes. Deloitte, an auditing and consulting company, has released data focused on the deals involving products and technologies in the biopharma arena. “Not surprisingly, oncology led the pack,” Silverman writes. “Cancer was the single most active therapeutic area with 161 deals, or 24 percent of all deals that were assigned a therapeutic area.” The report looked at 714 licensing deals and joint ventures, although only 245 disclosed deal size or upfront payments.